This resource does not offer CE through SGO. If you would like to claim the 0.25 CE available, please complete the course (same content) through the American Society for Clinical Pathology (ASCP) learning site. 

This microlearning activity is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of emerging research in HER2-directed therapies in gynecologic cancers and of treatment options based on HER2 results.  A particular focus of this activity is the DESTINY-PanTumor02 study and the latest evidence regarding HER2 testing, scoring and reporting in gynecologic cancers. The microlearning design of this activity allows for a brief and focused exploration of this topic.

Course topics include: 

• DESTINY-PanTumor02 and other trials evaluating HER2-directed therapies in gynecologic cancers 
• HER2 testing and scoring in endometrial, cervical, ovarian cancers 
• Specimen handling, scoring, reporting 
• Treatment implications based on HER2 results

Speakers/Authors:
Jennifer MacDonald, PharmD, BCOP
Clinical Pharmacy Specialist, Gynecologic Oncology
Hollings Cancer Center, Medical University of South Carolina

Sadia Sayeed, MD
Assistant Professor of Pathology, Director of Cytopathology, Department of Pathology
Virginia Commonwealth University Health

This activity was developed in partnership with the American Society for Clinical Pathology. This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.